An interventional study of RFR guided CABG and Angio guided CABG in Coronary Artery Disease, sponsored by Diagram B.V.. Recruiting at 4 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-01.
Sponsored by Diagram B.V. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 189 studies in Coronary Artery Disease with a site in Belgium — 26 open to participants now, 41 under way, 7 of them phase 3. Coronary Artery Disease · Belgium.
Among the 189 studies in Coronary Artery Disease with a site in Belgium, this one is the 57th largest by planned enrollment of the 148 interventional ones that give a count, is one of 11 that started in 2020, is one of 79 with no phase, reaches primary completion later than 9 of the 40 other live ones, and was the 137th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →26 of the 189 studies in Coronary Artery Disease with a site in Belgium are open now. Recruiting first, the newest first:
EBI Anti Sepsis BV · Sites in Belgium, United States, Netherlands and 1 more country
Ages 18+
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
Catharina Ziekenhuis Eindhoven · Sites in Belgium, Netherlands
Ages 18–85 · Healthy volunteers
Fundación EPIC · Sites in Belgium, United States, Spain and 1 more country
Ages 18–85
VZW Cardiovascular Research Center Aalst · Sites in Belgium
Ages 18+ · Healthy volunteers
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
189 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 19 · Phase 3 33 · Phase 4 21
First in 2002; this study’s year is marked. 11 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 282 across the 148 interventional studies, 332 across the 41 observational. Of the 127 that completed or were terminated, 45 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
115 of 189 have an industry lead sponsor. The 10 most frequent:
Diagram B.V. is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Diagram B.V. has 3 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
9 of the studies in Coronary Artery Disease with a site in Belgium that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05952206Phase 3iVascular S.L.U.Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy | 2027-01-13 |
| NCT07357675Phase 3EBI Anti Sepsis BVA Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery. | 2027-10-01 |
| NCT06095765Phase 3AZ Sint-Jan AVColchicine in Belgium in Patients With Coronary Artery Disease After Percutaneous Coronary Intervention | 2027-11-01 |
| NCT04545112XeltisXeltis Coronary Artery Bypass Graft (XABG) First in Human (FIH) | 2027-02 |
| NCT07036770Universitaire Ziekenhuizen KU LeuvenCoronary Evaluation And Guided Lesion Exploration Using Photon-counting CT and Intracoronary Imaging Techniques | 2027-05-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 189 studies in Coronary Artery Disease with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Different trials have shown that fractional flow reserve (FFR) could successfully guide revascularization in patients undergoing percutaneous coronary intervention (PCI).
It is conceivable that a similar revascularization guidance could be useful also for surgical revascularization i.e. coronary by-pass graft (CABG). Experience learns that grafts placed on vessels with hemodynamically non-significant stenosis often occlude due to competitive antegrade flow.
Resting full-cycle Flow Ratio (RFR) is a measurement performed to evaluate the hemodynamic severity of coronary stenosis. Differently from FFR which is a measurement performed in maximal hyperemia, the RFR is a measurement that is performed in rest and therefore may predict better than FFR the baseline equilibriums that could lead to graft failure, while it has similar capacity to identify hemodynamically significant stenosis as FFR. It is unknown whether RFR guided CABG revascularization is superior as compared to angiography alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
angiography guided CABG
Procedure: Angio guided CABG
RFR guided CABG
Procedure: RFR guided CABG
All patients will undergo RFR and FFR measurement before CABG. RFR and FFR values will be blinded to the patients. In the experimental arm the decision to revascularize will be based on RFR.
All patients will undergo RFR and FFR measurement before CABG. RFR and FFR values will be blinded to the patients. In the control arm the RFR values will be blinded to the cardiothoracic surgeon.
Number of participants who deceased, had a Myocardial Infarction (MI), Clinically-Driven Target Vessel Revascularization (CD-TVR), Stroke or Graft Dysfunction at 3 months post CABG
Time frame: 3 months
Cut-off value for the RFR that best predicts graft occlusion
Time frame: Baseline
Number of participants with graft dysfunction at 3 months post CABG
Time frame: 3 months
Major adverse cardiac or cerebrovascular event (MACCE), a composite of Death, MI, CD-TVR and Stroke at 1 year
Time frame: 1 year
Major adverse cardiac or cerebrovascular event (MACCE), a composite of Death, MI, CD-TVR and Stroke at 3 years
Time frame: 3 years
CD-TVR at 3 months post CABG
Time frame: 1 year
CD-TVR at 1 year post CABG
Time frame: 1 year
CD-TVR at 3 years post CABG
Time frame: 3 years
Not enrolling at this site.
Plan to share: Undecided — This has not been decided yet.
No publications or documents are linked to this record.
Started Feb 2020 (actual). Primary completion is estimated for Oct 2024, 56 months after the start.
Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 56 months is above that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Diagram B.V.